Archive for the ‘Cephalon’ Category
Feb
15
Posted under
Blog,
Cephalon,
Companies,
Diagnostics,
Funding,
Jeremy Levin,
laquinimod,
Medical Devices,
Medical Supply,
Pharmaceuticals,
Shire Pharmaceuticals,
Startups,
Teva Pharmaceutical Industries,
Universities,
Videos by John Carroll
Don't be too surprised if Teva starts to make fresh headlines on the M&A side of the business. CEO Shlomo Yanai is telling reporters the company is acutely aware of just how badly it needs to diversify its product base to cover falling revenue from its MS franchise. And with star Bristol-Myers Squibb ($BMY) dealmaker Jeremy Levin taking the helm from Yanai in May, analysts are buzzing about whether Teva ($TEVA) is thinking of pulling the trigger on a Shire takeover.
"Our answer is not just in developing drugs but in reducing our dependence on this product," Yanai told a news conference today, according to a report in Reuters. And Levin's looming arrival indicates for many that Teva sees a big future on the branded side of the biopharma business.
Revenue from branded drugs jumped 68% in the fourth quarter, a boost delivered by new drugs acquired in its Cephalon takeover. "During 2011 we made important progress in reaching our strategic goals with the acquisitions of Cephalon and Taiyo, and the creation of a unique joint venture with Procter & Gamble," Yanai told a news conference while covering the company's fourth quarter results. Its profits dropped 34% on acquisition costs.
Teva has had its own problems in drug development. Laquinimod, its next-gen MS treatment, recently flunked a late-stage study. And now Teva is working with regulators to design a new study for the therapeutic. Yanai says that Teva has a strong pipeline of experimental drugs.
- read the Reuters report
- get the Dow Jones story
Special Report: Jeremy Levin - The 25 most influential people in biopharma today
Related Articles:
New Teva CEO expected to replicate "string of pearls" deal strategy
Teva to bulk up in Asia with generics buyouts
Teva jacks up prices on Cephalon legacy brands
Feb
15
Posted under
Blog,
Cephalon,
Companies,
Diagnostics,
Funding,
Jeremy Levin,
Medical Devices,
Medical Supply,
Pharmaceuticals,
Shire Pharmaceuticals,
Startups,
Teva Pharmaceutical Industries,
Universities,
Videos by John Carroll
Don't be too surprised if Teva starts to make fresh headlines on the M&A side of the business. CEO Shlomo Yanai is telling reporters the company is acutely aware of just how badly it needs to diversify its product base to cover falling revenue from its MS franchise. And with star Bristol-Myers Squibb ($BMY) dealmaker Jeremy Levin taking the helm from Yanai in May, analysts are buzzing about whether Teva ($TEVA) is thinking of pulling the trigger on a Shire takeover.
"Our answer is not just in developing drugs but in reducing our dependence on this product," Yanai told a news conference today, according to a report in Reuters. And Levin's looming arrival indicates for many that Teva sees a big future on the branded side of the biopharma business.
Revenue from branded drugs jumped 68% in the fourth quarter, a boost delivered by new drugs acquired in its Cephalon takeover. "During 2011 we made important progress in reaching our strategic goals with the acquisitions of Cephalon and Taiyo, and the creation of a unique joint venture with Procter & Gamble," Yanai told a news conference while covering the company's fourth quarter results. Its profits dropped 34% on acquisition costs.
Teva has had its own problems in drug development. Laquinimod, its next-gen MS treatment, recently flunked a late-stage study. And now Teva is working with regulators to design a new study for the therapeutic. Yanai says that Teva has a strong pipeline of experimental drugs.
- read the Reuters report
- get the Dow Jones story
Special Report: Jeremy Levin - The 25 most influential people in biopharma today
Related Articles:
New Teva CEO expected to replicate "string of pearls" deal strategy
Teva to bulk up in Asia with generics buyouts
Teva jacks up prices on Cephalon legacy brands
Dec
19
Posted under
Blog,
Cephalon,
Companies,
Diagnostics,
Funding,
ImmuPharma,
Medical Devices,
Medical Supply,
Pharmaceuticals,
Startups,
Teva Pharmaceutical Industries,
Universities,
Videos by John Carroll
Partners: Cephalon (acquired by Teva)/ImmuPharma
Based: $TEVA - Jerusalem; $IMM - London
Termination date: October 2011
Length: 2.9 years
Deal: $500 million
Program: ImmuPharma's midstage lupus treatment
What went wrong: Cephalon only bet $15 million on the option pact when it lined up rights to the ImmuPharma program in 2008. If the Phase IIb trial was positive, Cephalon would have the rights to essentially take control and run Phase III.
In late 2009, though, ImmuPharma was insisting that although the trial had failed to hit the overall primary efficacy endpoint, the subgroup of patients they intended to study did respond positively. CEO Dimitri Dimitriou said some of the trial centers recruiting patients had never modified their patient selection to reflect an amended criteria, continuing to enlist patients who didn't fit the profile.
Cephalon was already convinced, handing over $30 million to exercise the licensing option. But then Teva Pharmaceutical Industries stepped in to buy Cephalon, and ImmuPharma noted in a release in October that it asked for the program back, as Teva has a competing lupus drug in the pipeline.
Nov
14
Posted under
Blog,
Cephalon,
Companies,
Diagnostics,
Funding,
Medical Devices,
Medical Supply,
Mesoblast,
Pharmaceuticals,
Revascor,
Startups,
Teva Pharmaceutical Industries,
Universities,
Videos by John Carroll
Mesoblast is taking center stage today at the American Heart Association's annual meeting with some impressive new data from a small mid-stage study of its stem cell therapy--Revascor--for heart failure. While only recruiting 45 patients for the trial, patients suffering from congestive heart failure demonstrated an 80% drop in the risk of further cardiac events. And while the treatment is still some years away from potential commercialization, analysts were pointing to the therapy's blockbuster potential if late-stage studies back up the early results.
Bell Potter Securities analyst Stuart Roberts, who has already touted the treatment's ability to rebuild heart muscle while improving blood flow, noted that this is the most detailed data yet seen on a treatment built out of mesenchymal stem cells, according to a report in Bloomberg. He added: "Applications in heart failure, in heart attacks and in chronic angina represent multibillion-dollar market opportunities."
Australia's Mesoblast has clearly impressed Cephalon ($CEPH) as well. The company, recently acquired by Teva ($TEVA), snagged a 20% stake in Mesoblast in a record $2 billion deal for Revascor late last year. Its U.S. president has called the treatment "potentially transformational."
- here's the article from Bloomberg
Related Articles:
Mesoblast to acquire Angioblast and speed up stem cell work
Cephalon strikes record $2B stem cell pact with Mesoblast